Translational Oncology · 2022 · 10 citations · 34 references
MedicinePharmacologyPharmacotherapyCancer PharmacologyMolecular OncologyProstate DiseaseAndrogen TherapyGenitourinary Cancer PharmacotherapyHormonal Cancer TherapyHormonal TherapyProstate CancerSteroid Hormone SignalingAdvanced Prostate Cancer TherapyAndrogen Receptor ExpressionCastration-resistant Prostate Cancer TherapyGrowth Inhibition AssaysProstate Cancer Hormonal TherapyStat3 SignalingTherapeutic Growth InhibitionWestern Blot Analysis
Enzalutamide is a second-generation anti-androgen which has shown increased survival in patients with metastatic prostate cancer. However, some patients do not respond to this therapy or will develop resistance to treatment over time. Signal Transducer and Activator of Transcription 3 (STAT3) is known to be involved in castration-resistant prostate cancer and to interact with androgen receptor (AR)-signaling. This study aims to investigate the combination enzalutamide and the small molecule STAT3 inhibitor GPB730 for enhanced therapeutic effect in advanced prostate cancer in vitro. The prostate cancer cell lines LNCaP (androgen dependent) and C4–2 (androgen insensitive) were used. The effect of enzalutamide and GPB730, alone and in combination, was investigated on viability and IC50 values calculated. Enzalutamide and GPB730 treated LNCaP and C4–2 cells were subjected to western blot and QPCR analyses in order to investigate the expression of AR, STAT3 and down-stream targets. C4–2 were less sensitive to growth inhibition by enzalutamide than LNCaP cells. GPB730 enhanced the growth inhibitory effect of enzalutamide in LNCaP and C4–2 cells. The addition of GPB730 to enzalutamide decreased the IC50 values for enzalutamide by 3.3-fold for LNCaP and by 12-fold for C4–2. In C4–2 cells, GPB730 alone decreased PSA expression and enhanced the enzalutamide induced decrease in NKX3.1 expression. GPB730 and enzalutamide in combination enhanced inhibition of c-myc and survivin expression. This study suggests that enzalutamide may be combined with the STAT3 inhibitor GPB730 in order to enhance the efficacy of enzalutamide, offering a new therapeutic approach in advanced prostate cancer.
34
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.6K citations · Full text
Medicine, Oncology, Pharmacology +14
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · New England Journal of Medicine · 2014 · 3K citations · Full text
Le Wang, Bin Lu, Mengjie He et al. · Frontiers in Public Health · 2022 · 643 citations · Full text